Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.

These S&P 500 stocks with dependable dividends and Buy ratings look like incredible contrarian ideas for growth and income ...

Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease MACHINE LEARNING MODEL USING ...

Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...